Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
14Dec2025
  • Home
  • About
  • News
  • Subscribe
14Dec2025
Cost Curve NewsCost Curve News
Cost Curve News

HRSA Annual 340B Data Release Is Out, and the Numbers Are Real, Real Big

On Thursday, I said that Cost Curve would be off until Monday “unless someone misbehaves.” I don’t know why I put that evil on myself. Because, sure enough, someone misbehaved. 
1 year ago
Keep Reading
Cost Curve News

Looking at the Ever-Morphing Report that PBMs Are Using In Their Anti-FTC Lawsuit

Programming Note: Unless someone misbehaves, Cost Curve will be off tomorrow. Back Monday. If you need extra Cost Curve content over the weekend, I sat down with Incubate’s John Stanford
1 year ago
Keep Reading
Cost Curve News

Looking Around the Corner at a Report from Minnesota That May Illuminate the 340B Program

I’ll have a bit tomorrow on the PBM lawsuit against the FTC, but if you’re looking for some PBM-related content today, you should check out Dr. Glaucomflecken on the legal
1 year ago
Keep Reading
Cost Curve News

A Barron’s Piece Lays Bare the PBM-Opioid Connection

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
1 year ago
Keep Reading
Cost Curve News

Breaking Down the Pharma Price-Control Math In Harris’ Home Care Proposal

Scheduling note: Cost Curve will be off tomorrow and Monday, back Tuesday. If you want to search Cost Curve back issues or link to anything you read here, the web
1 year ago
Keep Reading
Cost Curve News

A Huge Number of Employers Are Clueless About Where Their PBM Rebates Go

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
1 year ago
Keep Reading
Cost Curve News

The Evolution of Roche’s ‘Pharma Day’ Approach to Talking Pricing and Value

I know there are some new readers today, and, in the interest of expectation-setting, I wanted to reassure them that the newsletter isn’t usually this long. But I’ve been thinking
1 year ago
Keep Reading
Cost Curve News

Some Personal News: I’m Going to Start Working with Tufts CEVR

First, some personal news: I’m joining the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center as a senior fellow.  It’s an unparalleled opportunity to
1 year ago
Keep Reading
Cost Curve News

Gallup’s Industry Favorability Ratings Are Out, and Pharma Doesn’t Look So Good

Writing today from the lovely city of Minneapolis, where I am staying in a hotel in which every single room has a replica Herb Brooks sportcoat hanging on the wall.
1 year ago
Keep Reading
Cost Curve News

CMS Releases the Final Rules for the Next Set of Price Controls, Including Updates on How It’ll Gather Public Input

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
1 year ago
Keep Reading
272829

Latest Posts

A New Tracker for Watching Meds That Might See Prices Slashed

December 10, 2025

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

December 9, 2025

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

December 8, 2025

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

December 5, 2025

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

December 4, 2025

Popular

A New Tracker for Watching Meds That Might See Prices Slashed

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (2,940)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,032)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (1,922)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,721)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,714)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

A New Tracker for Watching Meds That Might See Prices Slashed

December 10, 2025

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

December 9, 2025

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2025 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe